{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:34:30Z","timestamp":1790282070454,"version":"4.1.0"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,11,15]]},"DOI":"10.2169\/internalmedicine.5072-24","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T18:07:16Z","timestamp":1747246036000},"page":"3238-3243","source":"Crossref","is-referenced-by-count":3,"title":["Immune Checkpoint Inhibitor-induced Mass-forming Pancreatitis and Lipodystrophy: A Case Report and Review of the Literature"],"prefix":"10.2169","volume":"64","author":[{"given":"Yuka","family":"Oi","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Yokohama Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Takayanagi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Yokohama Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Kakuta","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Yokohama Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Arioka","sequence":"additional","affiliation":[{"name":"Department of Oncology, Yokohama Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Matsunaga","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Yokohama Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. George J, Bajaj D, Sankaramangalam K, et al. Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: a systematic review and meta-analysis. Pancreatology 19: 587-594, 2019.","DOI":"10.1016\/j.pan.2019.04.015"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tanabe K, Yokoyama K, Kanno A, et al. Immune checkpoint inhibitor-induced pancreatitis with pancreatic enlargement mimicking autoimmune pancreatitis: a case report and review of the literature. Intern Med 63: 791-798, 2024.","DOI":"10.2169\/internalmedicine.1943-23"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60: 190-209, 2016.","DOI":"10.1016\/j.ejca.2016.02.025"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Shi W, Tan B, Li Y, et al. The diagnosis of immune-related pancreatitis disguised as multifocal lesions on MRI by endoscopic ultrasound-guided fine-needle biopsy: a case report. Front Immunol 13: 933595, 2022.","DOI":"10.3389\/fimmu.2022.933595"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hirota M, Murakami K, Koiwai A, et al. Neutrophil infiltration and acinar-ductal metaplasia are the main pathological findings in pembrolizumab-induced pancreatitis. Intern Med 61: 3675-3682, 2022.","DOI":"10.2169\/internalmedicine.9565-22"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ikemoto J, Ishii Y, Serikawa M, et al. Pembrolizumab-induced focal pancreatitis diagnosed by endoscopic ultrasound-guided fine-needle aspiration. Intern Med 61: 2463-2469, 2022.","DOI":"10.2169\/internalmedicine.8507-21"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Suda T, Kobayashi M, Kurokawa K, Matsushita E. Simultaneous occurrence of autoimmune pancreatitis and sclerosing cholangitis as immune-related adverse events of pembrolizumab. BMJ Case Rep 14: e243360, 2021.","DOI":"10.1136\/bcr-2021-243360"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Tanaka T, Sakai A, Shiomi H, et al. An autopsy case of severe acute pancreatitis induced by administration of pazopanib following nivolumab. Pancreatology 21: 21-24, 2021.","DOI":"10.1016\/j.pan.2020.11.002"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ueno M, Tsuji Y, Yokoyama T, et al. Fatal immune checkpoint inhibitor-related pancreatitis. Intern Med 60: 3905-3911, 2021.","DOI":"10.2169\/internalmedicine.7366-21"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Abu-Sbeih H, Tang T, Lu Y, et al. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer 7: 31, 2019.","DOI":"10.1186\/s40425-019-0502-7"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Dolladille C, Ederhy S, Sassier M, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol 6: 865-871, 2020.","DOI":"10.1001\/jamaoncol.2020.0726"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Wan G, Chen W, Khattab S, et al. Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study. Lancet Oncol 25: 1053-1069, 2024.","DOI":"10.1016\/S1470-2045(24)00278-X"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Tanaka T, Kusakabe T, Ebihara K, et al. Practice guideline for lipodystrophy syndromes - clinically important disease of the Japan Endocrine Society (JES). Endocr J 68: 1027-1042, 2021.","DOI":"10.1507\/endocrj.EJ21-0110"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Bedrose S, Turin CG, Lavis VR, Kim ST, Thosani SN. A case of acquired generalized lipodystrophy associated with pembrolizumab in a patient with metastatic malignant melanoma. AACE Clin Case Rep 6: e40-e45, 2020.","DOI":"10.4158\/ACCR-2019-0234"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Falcao CK, Cabral MCS, Mota JM, et al. Acquired lipodystrophy associated with nivolumab in a patient with advanced renal cell carcinoma. J Clin Endocrinol Metab 104: 3245-3248, 2019.","DOI":"10.1210\/jc.2018-02221"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Haddad N, Vidal-Trecan T, Baroudjian B, et al. Acquired generalized lipodystrophy under immune checkpoint inhibition. Br J Dermatol 182: 477-480, 2020.","DOI":"10.1111\/bjd.18124"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Jehl A, Cugnet-Anceau C, Vigouroux C, et al. Acquired generalized lipodystrophy: a new cause of anti-PD-1 immune-related diabetes. Diabetes Care 42: 2008-2010, 2019.","DOI":"10.2337\/dc18-2535"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Dhanasekaran M, Sandooja R, Higgins AS, Simha V. Marked hypoleptinemia precedes overt fat loss in immune checkpoint inhibitor-induced acquired generalized lipodystrophy. JCEM Case Rep 1: luad025, 2023.","DOI":"10.1210\/jcemcr\/luad025"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Drexler K, Zenderowski V, Berneburg M, Haferkamp S. Facial lipodystrophy after immunotherapy with nivolumab. J Dtsch Dermatol Ges 19: 1513-1515, 2021.","DOI":"10.1111\/ddg.14588"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Eigentler T, Lomberg D, Machann J, Stefan N. Lipodystrophic nonalcoholic fatty liver disease induced by immune checkpoint blockade. Ann Intern Med 172: 836-837, 2020.","DOI":"10.7326\/L19-0635"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Unal MC, Semiz GG. Ozdo\u011fan O, et al. Nivolumab associated endocrine abnormalities: challenging cases from a reference clinic. Acta Endocrinol (Buchar) 18: 516-522, 2022.","DOI":"10.4183\/aeb.2022.516"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/22\/64_5072-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T03:27:25Z","timestamp":1763177245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/22\/64_5072-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":21,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5072-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,15]]},"article-number":"5072-24"}}